1. Home
  2. INBX vs CDNA Comparison

INBX vs CDNA Comparison

Compare INBX & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Inhibrx Inc.

INBX

Inhibrx Inc.

HOLD

Current Price

$72.00

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Logo CareDx Inc.

CDNA

CareDx Inc.

HOLD

Current Price

$20.13

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INBX
CDNA
Founded
2010
1998
Country
United States
United States
Employees
161
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.0B
IPO Year
2020
2014

Fundamental Metrics

Financial Performance
Metric
INBX
CDNA
Price
$72.00
$20.13
Analyst Decision
Hold
Buy
Analyst Count
2
7
Target Price
N/A
$26.67
AVG Volume (30 Days)
218.5K
751.3K
Earning Date
11-14-2025
02-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
1.22
Revenue
$1,400,000.00
$357,998,000.00
Revenue This Year
$563.00
$14.47
Revenue Next Year
N/A
$11.35
P/E Ratio
N/A
$16.47
Revenue Growth
N/A
14.46
52 Week Low
$10.81
$10.96
52 Week High
$94.57
$25.55

Technical Indicators

Market Signals
Indicator
INBX
CDNA
Relative Strength Index (RSI) 41.77 55.38
Support Level $69.47 $16.94
Resistance Level $76.47 $21.20
Average True Range (ATR) 4.77 1.07
MACD -0.76 0.06
Stochastic Oscillator 20.55 71.21

Price Performance

Historical Comparison
INBX
CDNA

About INBX Inhibrx Inc.

Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.

About CDNA CareDx Inc.

CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.

Share on Social Networks: